N/A N=43 Health Services Research

Vitamin D Supplementation to Obese Chinese Males

Obesity · Insulin Resistance

Bottom Line

View on ClinicalTrials.gov: NCT01781169 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2013

Primary outcome: Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Oral supplementation of vitamin D (Dietary_supplement)
Age: Adult, Older Adult · 23+ yrs
Sex: Male
Sponsor: Shenzhen Center for Chronic Disease Control
Primary completion: Dec 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L)	116.7; 181.3; 46.1; 52.8	—

Summary

Hypothesis: Oral Supplementation of Vitamin D can Reduce Hypersecretion of Parathyroid Hormone and Insulin Resistance in Obese Chinese Males. Protocol: Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) or eight weeks to the obese males compared with the normal-weight males. Index measures were conducted at baseline and endpoint.

Eligibility Criteria

Inclusion Criteria

body mass index (BMI) ≥ 28kg/m2 or 18.5 ≤ BMI 2 y
fasting serum glucose < 7.0 mmol/L
serum glucose of 2 hr after 75 g oral glucose loading < 11.1 mmol/L
normal functioning of liver and kidney evaluated by alkaline phosphatase, aspartate aminotransferase, creatinine, and uric acid

Exclusion Criteria

not match the above inclusion criteria
diagnosed as having any organic diseases were excluded

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01781169). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.